In line with the antagonistic relationship between p53 and NF-κB, the diminished p53 activity in UXT-expressing cancer cells was associated with an elevated NF-κB activity, which was initially uncovered by the pathway screening and subsequently validated by examining p65 nuclear distribution and phosphorylation. Here, TP53 is linked to cancer.